Apimeds Pharmaceuticals US, Inc. GAAP EPS of $7.68, revenue of $2.89M
Apimeds Pharmaceuticals US, Inc. reported Q3 GAAP EPS of $7.68 and revenue of $2.89M, according to the company's press release.
Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US develops Apitox, an intradermally administered, purified honeybee venom product, through its wholly owned subsidiary Lokahi Therapeutics. The clinical-stage biopharmaceutical company focuses primarily on developing Apitox for inflammation and pain symptoms associated with knee osteoarthritis, with multiple sclerosis as a secondary area of interest. Apitox is made as a lyophilized powder for reconstitution before injection. Lokahi has a license to use prior clinical development data associated with Apitoxin, which is marketed in South Korea by Apimeds Korea; Apimeds Pharmaceuticals US is not associated with its South Korean sales. The company conducts business through Lokahi and MindWave Innovations Inc. Its activities include developing Apitox in the United States and partnering with universities to provide students hands-on exposure to biopharmaceutical strategy. Lokahi’s ai² Futures Lab™ serves as a discovery engine for potential therapeutic assets and a training ground for biotech and business leaders. The company is headquartered in Matawan, New Jersey.
No SEC Form 4 filings for $APUS in the last 30 days.
See all $APUS insider activity →Apimeds Pharmaceuticals US, Inc. reported Q3 GAAP EPS of $7.68 and revenue of $2.89M, according to the company's press release.
MindWave, a subsidiary of Apimeds Pharmaceuticals (APUS), formed a joint venture with Skalup Capital to establish Monaco Insurance in Bermuda. MindWave holds 75% equity, focusing on blockchain-based insurance tech. Skalup manages underwriting and distribution. The venture targets life annuities and general insurance, pending regulatory approvals. APUS may benefit from this strategic move.
Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network AssureChain, a dedicated subnet of MindChain, will run every insurance function on-chain, while MindChain provides settlem
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning APUS (Apimeds Pharmaceuticals US, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent APUS coverage spans financial news, technology and corporate actions.
The earnings print provides a fresh datapoint for APUS’s quarterly profitability and top-line, which can drive near-term repricing versus expectations.
The JV introduces a new revenue stream and exposure to digital-asset insurance, which could be viewed positively by investors.
The contract adds a new revenue stream and exposure to the growing insurance‑tech blockchain market.
New contracts may boost future earnings and improve sentiment.
The contract adds a recurring services revenue source for the subsidiary, potentially boosting APUS's top line over the next two years.
AlphAI scores every news story that mentions APUS with an AI model for sentiment and relevance, and aggregates insider trades from Apimeds Pharmaceuticals US, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Apimeds Pharmaceuticals US, Inc. reported Q3 GAAP EPS of $7.68 and revenue of $2.89M, according to the company's press release.
MindWave, a subsidiary of Apimeds Pharmaceuticals (APUS), formed a joint venture with Skalup Capital to establish Monaco Insurance in Bermuda. MindWave holds 75% equity, focusing on blockchain-based insurance tech. Skalup manages underwriting and distribution. The venture targets life annuities and general insurance, pending regulatory approvals. APUS may benefit from this strategic move.
Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network AssureChain, a dedicated subnet of MindChain, will run every insurance function on-chain, while MindChain provides settlem
MindWave Innovations, a subsidiary of Apimeds Pharmaceuticals (NYSE: APUS), signed three agreements to build and operate blockchain networks for AQUAE, Flash Sports & Media (FLZH), and BlockAssure. The networks will operate on MindChain and MindWave will earn fees, equity, or token allocations. APUS previously disclosed substantial doubt about its ability to continue as a going concern.
MindWave Innovations (APUS) signed a 2-year agreement with BlockAssure to build and operate AssureChain, an insurance and reinsurance network on MindChain. MindWave will earn development fees and receive 20% of AssureCoin's total supply. The agreement took effect on Oct. 4, 2026, and includes automatic renewal clauses.
Apimeds Pharmaceuticals US (APUS) appointed Eric Sherb as CFO on October 1, 2026, following Erick Frim's resignation as Interim CFO on September 29, 2026. Sherb has 18+ years of capital markets experience and is a Certified Public Accountant. Frim's departure was not due to any disagreement with the company.
Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Interim Chief Financial Officer On September 29, 2026, Erick Frim notified Apimeds Pharmaceuticals US, Inc.,
Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 MindWave Innovations Inc to Power AQUAEChain with Its MindChain Blockchain Infrastructure Agreement strengthens MindWave’s position as a technology provider for ecosystem finance and environmental markets MATAWAN, New Jersey — September 24, 2026 — MindWave Innovation
Meta (META) rose 4.5% to $777.59, driven by AI strategy. Everpure (P) surged 11.15% to $121.88, reaffirming fiscal 2027 guidance. Akamai (AKAM) fell 6.78% to $110.41, then jumped 20.65% after-hours on a $11.6B AI deal. Apimeds (APUS) soared 114.85% to $4.92 on a blockchain agreement. Costco (COST) dipped 0.91% to $896.48 despite beating Q4 estimates.
Biotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.